A5077228703- MicroRNA in disease regulation
- Extracellular vesicles in disease
- Immune cells in cancer
- Cancer-related molecular mechanisms research
- Circular RNAs in diseases
- Sarcoma Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Immunotherapy and Biomarkers
Fondazione IRCCS Istituto Nazionale dei Tumori
2022-2023
PD-L1 in tumor cells is the only used biomarker for anti PD1/PD-L1 immune-checkpoints inhibitors (ICI) Non Small Cell Lung Cancer (NSCLC) patients. However, this parameter inaccurate to predict response, especially patients with low PD-L1. Here, we evaluated circulating EVs as possible biomarkers ICI advanced NSCLC tumoral were isolated from plasma of 64 low, ICI-treated patients, classified either responders (R; complete or partial response by RECIST 1.1) non-responders (NR). characterized...
Adolescents and young adults (AYA) with rhabdomyosarcoma (RMS) form a subgroup of patients whose optimal clinical management best possible access to care remain challenge survival rates lag behind that children diagnosed histologically similar tumors. A better understanding tumor biology differentiates (PEDS-) from AYA-RMS could provide critical information drive new initiatives improve their final outcome. We investigated the functional role miRNAs implicated in development, as they have...
Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer development. COPD induces activation of hypoxia-induced signaling, causing remodeling surrounding microenvironmental cells also modulating the release and cargo their extracellular vesicles (EVs). We aimed to evaluate potential role circulating EVs from subjects in onset. Plasma-EVs were isolated by ultracentrifugation heavy smoker volunteers with (COPD-EVs) or without (heavy smoker-EVs, HS-EV) characterized...